Biome's International Market Expansion Update

Biome Australia Limited (ASX: $BIO) has reported positive early sales revenue growth in international markets following its recent health retail launch in the United Kingdom and Ireland. The company expects FY24 international sales revenue to exceed $850k, representing an 85% growth compared to the previous corresponding period (FY23 $459k). Biome has also secured approval from Health Canada for eight product registrations, with plans for further expansion into Western European markets in FY25.

Executive Commentary on International Expansion

Biome Australia's Managing Director and Founder, Blair Vega Norfolk, stated, 'This measured step in our international expansion is a critical milestone in establishing Biome's products with health professionals globally. Our goal is to position Activated Probiotics as the obvious choice when health professionals recommend a probiotic to their patients.'

Summary of International Market Update and Future Outlook

Biome Australia Limited (ASX: $BIO) has demonstrated strong growth in international sales revenue and achieved approvals from Health Canada for its products. The company anticipates further expansion into Western European markets in FY25 and plans a test market launch into North America via Canada in H2 FY25. With a focus on replicating the trust and loyalty developed locally, Biome aims to establish its products with health practitioners and patients in Europe and North America. The Health Canada approvals are expected to provide significant credibility for Biome's products beyond Canada and into the United States market in the future. The company's commitment to educating health professionals and its innovative, evidence-based natural medicines position it for continued success in addressing prevalent and chronic health concerns.